0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%

Craneware Plc

Healthcare GB CRW

2215.0GBP
-5.0(0.23%)

Last update at 2024-12-24T12:44:00Z

Day Range

2189.002243.00
LowHigh

52 Week Range

1049.661932.02
LowHigh

Fundamentals

  • Previous Close 2220.00
  • Market Cap636.30M
  • Volume15085
  • P/E Ratio85.71
  • Dividend Yield1.58%
  • EBITDA42.51M
  • Revenue TTM174.02M
  • Revenue Per Share TTM4.95
  • Gross Profit TTM 148.44M
  • Diluted EPS TTM0.21

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 13.09M 13.10M 13.16M 19.30M 18.32M
Minority interest - - - - -
Net income 9.23M 9.41M 12.90M 16.84M 14.98M
Selling general administrative 20.38M 20.38M 9.30M 9.98M 8.72M
Selling and marketing expenses 15.27M 15.27M 6.62M 7.21M 9.73M
Gross profit 148.44M 142.37M 70.20M 66.97M 67.01M
Reconciled depreciation 32.16M 29.40M 5.24M 4.67M 3.53M
Ebit 17.38M 20.24M 19.73M 19.40M 18.00M
Ebitda 49.54M 49.64M 24.97M 24.06M 23.94M
Depreciation and amortization 32.16M 29.40M 5.24M 4.67M 5.93M
Non operating income net other - - - - -
Operating income 19.23M 18.13M 13.24M 19.21M 18.00M
Other operating expenses 156.85M 145.11M 55.80M 52.27M 52.16M
Interest expense 6.36M 5.03M 0.08M 0.09M 2.09M
Tax provision 3.85M 3.69M 0.26M 2.47M 3.34M
Interest income 0.21M 0.00100M 0.00100M 0.19M 0.32M
Net interest income -6.14300M -5.03000M -0.07500M 0.10M 0.32M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.85M 3.69M 0.26M 2.47M 3.34M
Total revenue 174.02M 165.54M 75.58M 71.49M 71.40M
Total operating expenses 131.28M 121.93M 50.43M 47.76M 47.76M
Cost of revenue 25.58M 23.18M 5.37M 4.52M 4.39M
Total other income expense net -6.65300M -7.13600M -6.56200M 0.10M 0.32M
Discontinued operations - - - - -
Net income from continuing ops 9.23M 9.41M 12.90M 16.84M 14.98M
Net income applicable to common shares 9.23M 9.41M 12.90M 16.84M 14.98M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 576.98M 568.79M 311.60M 115.76M 106.30M
Intangible assets 216.56M 230.69M 31.92M 25.59M 19.25M
Earning assets - - - - -
Other current assets 41.25M 41.25M 19.43M 21.00M 18.79M
Total liab 249.13M 235.77M 51.32M 47.36M 46.47M
Total stockholder equity 327.84M 333.02M 260.28M 68.39M 59.84M
Deferred long term liab - 0.03M 1.69M - -
Other current liab 0.14M 0.02M 0.43M 44.63M 38.93M
Common stock 0.66M 0.66M 0.62M 0.54M 0.54M
Capital stock 0.66M 0.66M 0.62M 0.54M 0.54M
Retained earnings 39.88M 42.24M 46.83M 42.60M 35.72M
Other liab 44.45M 48.17M 0.76M - -
Good will 235.24M 237.65M 11.19M 11.19M 11.19M
Other assets 2.76M 3.23M 10.89M 6.32M 8.19M
Cash 78.54M 47.16M 235.62M 47.85M 47.61M
Cash and equivalents - - - - -
Total current liabilities 127.38M 82.51M 49.41M 45.35M 46.47M
Current deferred revenue 113.85M 58.70M 32.19M -7.62100M -
Net debt 8.15M 65.93M -234.46900M -45.83400M -47.61100M
Short term debt 9.39M 8.00M 1.05M 0.95M -
Short long term debt 8.00M 8.00M - - -
Short long term debt total 86.69M 113.08M 1.15M 2.02M -
Other stockholder equity -40.54400M -42.89500M -47.45200M -43.14100M 23.58M
Property plant equipment 8.46M 8.82M 2.55M 3.80M 1.27M
Total current assets 113.96M 88.41M 255.05M 68.85M 66.40M
Long term investments - - - - -
Net tangible assets -123.95200M -135.31100M 217.17M 31.61M 29.40M
Short term investments - - - - -
Net receivables 24.17M 35.31M 17.04M 18.95M 16.86M
Long term debt 75.03M 103.59M - - -
Inventory - - - - -
Accounts payable 4.00M 15.79M 15.74M 7.39M 7.53M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -4.80200M -3.31300M
Additional paid in capital - - - - -
Common stock total equity - - 0.62M 0.54M 0.54M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -460.25700M 3.23M -45.66200M -40.58100M 4.95M
Deferred long term asset charges - - - - -
Non current assets total 463.01M 480.39M 56.55M 46.90M 39.90M
Capital lease obligations 3.66M 1.50M 1.15M 2.96M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -15.33700M -307.32000M -10.32500M -9.70900M -10.43400M
Change to liabilities -5.46200M -13.50000M 4.20M -0.87200M -1.79300M
Total cashflows from investing activities -15.33700M -307.32000M -10.32500M -9.70900M -10.43400M
Net borrowings -30.55200M 109.97M -0.96400M -1.00300M -1.00300M
Total cash from financing activities -53.28200M 91.90M 174.55M -10.72100M -8.25100M
Change to operating activities 50.55M 50.55M 50.55M 50.55M -
Net income 13.09M 13.10M 13.16M 19.30M 18.32M
Change in cash 31.38M -188.46000M 187.77M 0.24M -5.22200M
Begin period cash flow 47.16M 235.62M 47.85M 47.61M 52.83M
End period cash flow 78.54M 47.16M 235.62M 47.85M 47.61M
Total cash from operating activities 98.75M 26.96M 23.54M 20.67M 13.46M
Issuance of capital stock -0.04100M 1.49M 187.33M 0.61M 0.25M
Depreciation 32.16M 29.40M 5.24M 4.67M 3.53M
Other cashflows from investing activities 0.21M 0.00100M 0.00100M 0.00100M 0.00100M
Dividends paid 12.12M 12.98M 9.70M 9.08M 8.50M
Change to inventory - - - - -
Change to account receivables 1.12M -3.20300M 2.03M -1.18300M -5.95700M
Sale purchase of stock -3.81500M -1.72600M -0.42200M -1.25500M 0.25M
Other cashflows from financing activities -9.30700M 116.09M 184.25M 2.15M -10.43400M
Change to netincome 11.15M 4.85M -0.83400M 1.22M 2.70M
Capital expenditures 15.55M 14.03M 10.33M 9.71M 10.43M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 46.20M -16.70200M 6.22M -2.05500M -7.75000M
Stock based compensation 2.99M 2.12M 2.14M 1.32M 1.30M
Other non cash items 6.14M 5.03M 0.07M -0.09800M -0.31800M
Free cash flow 83.20M 12.93M 13.21M 10.96M 3.03M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRW
Craneware Plc
-5.0 0.23% 2215.00 85.71 26.53 3.65 2.44 3.65 12.32
INHC
Induction Healthcare Group PLC
- -% 9.00 - 21.51 1.76 0.96 1.48 -1.6421
RENX
Renalytix AI plc
- -% 10.75 - - 6.44 8.06 3.81 -0.2835
COG
Cambridge Cognition Holdings Plc
- -% 34.00 - 238.10 1.42 18.04 0.76 -2.6598
FDBK
Feedback PLC
- -% 16.75 - - 9.56 0.89 2.29 -0.8995

Reports Covered

Stock Research & News

Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers Trisus Decision Support; Trisus Labor Productivity; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, it offers appeal, professional, and pharmacy professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.

Craneware Plc

1 Tanfield, Edinburgh, United Kingdom, EH3 5DA

Key Executives

Name Title Year Born
Mr. Keith Neilson Co-Founder, CEO & Exec. Director 1969
Mr. Craig Thomas Preston ACA CFO, Company Sec. & Exec. Director 1971
Ms. Isabel Urquhart Chief People Officer & Director 1968
Mr. Abhilesh Gandhi Group Chief Technology Officer NA
Mr. Derek William Paterson Chief Information Officer 1968
Mr. Eric Carter Chief Legal Officer NA
Mr. Mark Montgomery Chief Marketing Officer NA
Mr. Seth Droe Chief Revenue Officer NA
Ms. Karen Bowden RHIA Exec. VP of Customer Management NA
Ms. Lidia A. Rodriguez-Hupp Chief Customer Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions